Professor of Medicine; Director, Advanced Heart Failure and Transplant

Vanderbilt Heart and Vascular Institute

Printed as of 5/7/2024

# **Disclosures**

Personal Commercial (*	16)	
------------------------	-----	--

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Abbott	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Alleviant	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Astra Zeneca	Research/Research Grants ‡ DEFINE-HF	None (\$0)	Heart Failure and Cardiomyopathies
AstraZeneca	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Boehringer Ingelheim Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Boston Scientific	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Cordio	Consultant Fees/Honoraria	None (\$0)	Heart Failure and Cardiomyopathies
CVRx	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Edwards	Consultant Fees/Honoraria	Modest (< \$5,000)	Valvular Heart Disease
Impulse Dynamics	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Merck	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Merck & Co., Inc.	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Novartis	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Sensible Medical	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
Volumetrix	Research/Research Grants	None (\$0)	Heart Failure and Cardiomyopathies
VWAVE	Consultant Fees/Honoraria	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies

# Additional Personal Commercial Disclosures for Education Activities (1)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Medtronic	Consultant Fees/Honoraria	None (\$0)	Heart Failure and Cardiomyopathies

# Personal Organizational or Other Non-Commercial (0)

No disclosures on record

# Clinical Trial Enroller (1)

Trial Name	Trial Sponsor	Trial Funding Source
DICTATE-AHF	Astra Zeneca	Astra Zeneca

# Institutional Financial Decision-Making Role (2)

Funding Source	Institutional Compensation Level
Astra Zeneca	None (\$0)
VoluMetrix	None (\$0)

# Expert Witness Testimony (0)

No disclosures on record

# **Agreement**

Certified Education Attestation | Signed on 9/28/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/28/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 9/28/2023

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 9/28/2023

### **ACC** and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.